Etilevodopa

Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD) . Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].

Product Specifications

CAS Number

[37178-37-3]

Product Name Alternative

L-DOPA ethyl ester; Levodopa ethyl ester

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Dopamine Receptor; Drug Metabolite

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/etilevodopa.html

Purity

99.00

Solubility

H2O : 12 mg/mL (ultrasonic; warming)

Smiles

N[C@H](C(OCC)=O)CC1=CC=C(C(O)=C1)O

Molecular Formula

C11H15NO4

Molecular Weight

225.24

Precautions

H302, H319

References & Citations

[1]Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26 (6) :322-6.|[2]Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63 (2) :210-6.|[3]Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23 (1) . pii: E40.